

GLP-1 Use in Arkansas Health Network Patients


GLP-1 receptor agonists are costly but transformative in T2D management due to their A1C and weight loss benefits. **With nearly 4,000 Arkansas Health Network (AHN) patients currently prescribed a GLP-1 and an impressive 89.1% achieving controlled A1C levels, these therapies are demonstrating both a clinical and financial impact within our population.** See below for more detailed information.

GLP-1 Medications

Brand Name	Generic Name	Cost Per Day	Dosing	Route	For Weight Loss	Reduces CVD Risk	Reduces CKD Risk
Mounjaro	Tirzepatide	\$33.52	Weekly	Sub-Q	Zepbound	-	-
Trulicity	Dulaglutide	\$32.28	Weekly	Sub-Q	-	Yes	-
Ozempic	Semaglutide	\$30.92	Weekly	Sub-Q	Wegovy	Yes	Yes
Rybelsus	Semaglutide	\$29.14	Daily	Orally	-	-	-
Victoza	Liraglutide	\$23.79	Daily	Sub-Q	Saxenda	Yes	-

Number of AHN patients on GLP-1	3,943
Total spend on GLP-1 in 2024 (across all contracts)	\$ 13,481,942.00
% of patients with a T2D diagnosis	97%
% of patients on GLP-1 with controlled A1C	89.1%

Comparing Effectiveness and Side Effects



Breakdown by Contract

Contract Name	Total	No Diagnosis	Uncontrolled	Unknown	Known	% Uncontrolled
MA 1	78	2	2	16	62	3%
MA 2	388	14	64	144	244	26%
Employer 1	58	0	0	22	36	0%
Employer 2	99	0	17	13	86	20%
Employer 3	13	0	2	0	13	15%
Employer 4	66	16	4	33	33	12%
Commercial ACO (hybrid fully insured/Medicaid)	764	4	73	146	618	12%
MSSP ACO	522	10	6	78	444	1%
Total	1988	46	168	452	1536	10.9%